To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)

This study is testing a cell therapy where a patient's own immune cells are re-engineered to attack cancer (CAR-T cell therapy) for people with B-cell non-Hodgkin lymphoma (a type of blood cancer) that has returned or not responded to prior treatments. **You may be eligible if...** - You have confirmed CD19-positive B-cell non-Hodgkin lymphoma - Your lymphoma came back within one year after stem cell transplant, OR you are resistant to second-line treatment with no curative options available - You are between 13 and 75 years old - You have adequate kidney and liver function - You have at least one measurable tumor **You may NOT be eligible if...** - You do not have CD19-positive lymphoma - You have significant organ dysfunction (kidney or liver problems) - You have active uncontrolled infections - You have had prior CAR-T cell therapy Talk to your doctor to see if this trial is right for you.